Australia - English - Department of Health (Therapeutic Goods Administration)

hologic (australia & new zealand) pty ltd - ct793 - neisseria ivds - the aptima neisseria gonorrhoeae assay is a target amplification nucleic acid probe test that utilizes target capture for the in vitro qualitative detection of ribosomal rna (rrna) from neisseria gonorrhoeae (gc) to aid in the diagnosis of gonococcal urogenital disease

Australia - English - Department of Health (Therapeutic Goods Administration)

becton dickinson pty ltd - ct793 - neisseria ivds - an in vitro diagnostic test intended for testing of neisseria gonorrhoeae (gc).

Australia - English - Department of Health (Therapeutic Goods Administration)

becton dickinson pty ltd - ct793 - neisseria ivds - ivds that are used for the qualitative detection of neisseria bacteria in clinical specimens.

Australia - English - Department of Health (Therapeutic Goods Administration)

in vitro technologies pty ltd - ct793 - neisseria ivds - ivds that are intended to be used in testing to provide information about infection with or exposure to neisseria bacteria in nucleic acid extracted from whole blood, cerebrospinal fluid, and nasopharyngeal swab specimens.

Australia - English - Department of Health (Therapeutic Goods Administration)

speedx pty ltd - ct793 - neisseria ivds - ivds that are intended to be used in testing to provide information about infection or exposure to neisseria bacteria

Kenya - English - Pharmacy and Poisons Board

sanofi pasteur s.a. 2 avenue pont pasteur 69007 lyon france - neisseria meningitidis serogroup a c y and w-135… - solution for injection - each 0.5 ml dose contains 4 mcg of each … - bacterial vaccines: meningococcal vaccines

European Union - English - EMA (European Medicines Agency)

gsk vaccines s.r.l. - outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254), recombinant neisseria meningitidis group b fhbp fusion protein, recombinant neisseria meningitidis group b nada protein, recombinant neisseria meningitidis group b nhba fusion protein - meningitis, meningococcal - meningococcal vaccines - active immunisation against invasive disease caused by neisseria meningitidis serogroup-b strains.,

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - meningococcal oligosaccharide - group c 10ug (conjugated with 5 mcg diphtheria crm 197 protein);   - suspension for injection - 0.5 ml - active: meningococcal oligosaccharide - group c 10ug (conjugated with 5 mcg diphtheria crm 197 protein)   excipient: aluminium phosphate sodium chloride water for injection - active immunisation of children from 6 weeks of age, adolescents and adults for the prevention of invasive disease caused by neisseria meningitidis serogroup c.

European Union - English - EMA (European Medicines Agency)

gsk vaccines s.r.l. - meningococcal group a, c, w-135 and y conjugate vaccine - immunization, meningitis, meningococcal - bacterial vaccines - prefilled syringe menveo is indicated for active immunisation of adolescents (from 11 years of age) and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations. vials menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to neisseria meningitidis groups a, c, w135 and y, to prevent invasive disease. the use of this vaccine should be in accordance with official recommendations.,

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - neisseria meningitidis group b factor h binding protein fusion protein 50ug; neisseria meningitidis group b neisseria adhesin a protein 50ug; neisseria meningitidis group b neisseria heparin binding antigen fusion protein 50ug; neisseria meningitidis sergroup b outer membrane vesicles 25ug;   - suspension for injection - 0.5 ml - active: neisseria meningitidis group b factor h binding protein fusion protein 50ug neisseria meningitidis group b neisseria adhesin a protein 50ug neisseria meningitidis group b neisseria heparin binding antigen fusion protein 50ug neisseria meningitidis sergroup b outer membrane vesicles 25ug   excipient: aluminium hydroxide histidine sodium chloride sucrose water for injection - bexsero is indicated for active immunisation against invasive disease caused by n. meningitidis group b strains. see section 5.1 of the data sheet for information on protection against specific group b strains bexsero is indicated for vaccination of individuals from 2 months of age and older. the use of bexsero should be in accordance with official recommendations.